CIITA and graft versus host disease: One such product utilizes CRISPR-Cas9 to simultaneously knock-out the TCR α chain to prevent GvHD, as well as HLA-A/B, CIITA, and PD-1 to evade host-mediated immune rejection and enhance persistence (66).